Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Gemcitabine and docetaxel versus doxorubicin as first-lin... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
0
Authors
Beatrice Seddon
18 more
Beatrice Seddon
•
Sandra Strauss
16 more
•
Sandy Beare
Published
September 5, 2017
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Medicine
Cancer Oncology
Pathology
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s1470-2045(17)30622-8
License
CC-BY-NC-ND
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Medicine
Cancer Oncology
Pathology
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s1470-2045(17)30622-8
License
CC-BY-NC-ND
Other Formats
PDF
